<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081964</url>
  </required_header>
  <id_info>
    <org_study_id>PB-101-200</org_study_id>
    <nct_id>NCT01081964</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia</brief_title>
  <official_title>A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IASO Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IASO Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens&#xD;
      of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy,&#xD;
      active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl&#xD;
      (400mg) versus oral levofloxacin (500mg) in the treatment of adults with community-acquired&#xD;
      pneumonia of moderate severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Financial considerations&#xD;
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 35 days after first dose</time_frame>
    <description>Assess safety through monitoring of adverse events, ECGs, and the collection of conventional laboratory data (i.e., chemistry panel, CBC with differential, urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the two dosing regimens of zabofloxacin</measure>
    <time_frame>Up to 35 days after first dose</time_frame>
    <description>Determine the clinical response and microbiological response of two dosing regimens in the treatment of bacteriologically confirmed CAP of moderate severity; determine the pharmacokinetic profile in subjects with CAP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Levofloxacin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500mg once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zabofloxacin 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zabofloxacin 400mg for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zabofloxacin 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zabofloxacin 400mg for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin</intervention_name>
    <description>Zabofloxacin 400mg capsule once daily for 3 days</description>
    <arm_group_label>Zabofloxacin 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Levofloxacin 500mg orally for 7 days</description>
    <arm_group_label>Levofloxacin 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin 400mg</intervention_name>
    <description>Zabofloxacin 400mg orally for 5 days</description>
    <arm_group_label>Zabofloxacin 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female &gt;/= 18 years old&#xD;
&#xD;
          -  Documented fever (oral &gt;100°F (37.8°C), tympanic &gt;101°F (38.1°C)must be documented&#xD;
             within the time frame of 24 hours prior to first dose through 24 hours after first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Community-acquired pneumonia of moderate severity (defined as PSI Risk Class II or&#xD;
             III) requiring administration of antibiotics&#xD;
&#xD;
          -  Dyspnea and/or tachypnea (&gt;20 breaths/minute)&#xD;
&#xD;
          -  Clinical diagnosis of pneumonia, as demonstrated by all of the following signs and&#xD;
             symptoms:&#xD;
&#xD;
               1. new or increased cough&#xD;
&#xD;
               2. production of purulent sputum or a change in the character of sputum in subjects&#xD;
                  who normally have purulent sputum&#xD;
&#xD;
               3. auscultatory findings on pulmonary examination of rales and/or evidence of&#xD;
                  pulmonary consolidation (e.g., bronchial breath sounds, egophony, or dullness on&#xD;
                  percussion)&#xD;
&#xD;
          -  Females must be surgically sterile (e.g., tubal ligation, hysterectomy),&#xD;
             post-menopausal at least 2 years, or if of childbearing potential, they must have a&#xD;
             negative urine pregnancy test (β-human chorionic gonadotropin [β-hCG]) prior to&#xD;
             randomization into the study. Males and females must agree that if they have&#xD;
             intercourse that they will use at least two medically accepted methods of birth&#xD;
             control (e.g., hormonal contraceptive, intrauterine device, spermicide, or condom)&#xD;
             from study entry through 60 days after discontinuation of study drug treatment&#xD;
&#xD;
          -  Able to give written informed consent in a manner approved by the Institutional Review&#xD;
             Board or Ethics Committee and comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must NOT meet any of the following exclusion criteria:&#xD;
&#xD;
          -  Received one or more doses of any systemic antibiotic in the last 2 weeks&#xD;
&#xD;
          -  Diagnosed with any other infection requiring systemic antibacterial therapy&#xD;
&#xD;
          -  Require long-term (&gt;7 days) antibiotic therapy&#xD;
&#xD;
          -  Previous diagnosed condition that might mimic or complicate the course and evaluation&#xD;
             of the infectious disease process (e.g., septic shock, bronchiectasis, lung abcess or&#xD;
             empyema, aspiration pneumonia, active tuberculosis, pulmonary malignancy, cystic&#xD;
             fibrosis, post-obstructive pneumonia, etc.)&#xD;
&#xD;
          -  Hypothermia (oral &lt;96°F [35.6°C}, tympanic &lt;97°F [35.9°C]&#xD;
&#xD;
          -  Hospitalization (inpatient) in the previous 60 days or infection presumably acquired&#xD;
             in the hospital&#xD;
&#xD;
          -  Resident of a skilled nursing facility anytime in the previous 60 days or infection&#xD;
             presumably acquired in a skilled nursing facility&#xD;
&#xD;
          -  Chronic infection with Hepatitis B&#xD;
&#xD;
          -  Any evidence of, or is a known carrier of , Hepatitis C antibody&#xD;
&#xD;
          -  Infection with Clostridium difficile&#xD;
&#xD;
          -  Immunocompromising illness, including known human immunodeficiency virus (HIV)&#xD;
             positivity or AIDS, organ (bone marrow) transplant recipients, and hematological&#xD;
             malignancy&#xD;
&#xD;
          -  Psychotic disease, peripheral neuropathy, and glucose-6-phosphate dehydrogenase&#xD;
             deficiency; uncontrolled or poorly controlled diabetes. Diabetic subjects who are&#xD;
             stable and on a stable course of antihyperglycemic agents for the past 3 months will&#xD;
             be permitted in the trial.&#xD;
&#xD;
          -  High exposure to sunlight or ultraviolet radiation&#xD;
&#xD;
          -  Immunosuppressive therapy, including cancer chemotherapy or chronic use of&#xD;
             corticosteroids (i.e., &gt;20mg prednisone or equivalent per day for &gt;/= 14 days within&#xD;
             the last 6 months&#xD;
&#xD;
          -  History of renal or hepatic disease as defined by at least one of the following:&#xD;
&#xD;
               1. Calculated creatinine clearance &lt;50 mL/min (any subject on dialysis must be&#xD;
                  excluded)&#xD;
&#xD;
               2. BUN &gt;/= 30 mg/dL&#xD;
&#xD;
               3. ALT or AST &gt; 3x ULN&#xD;
&#xD;
               4. Total bilirubin &gt; 2x ULN&#xD;
&#xD;
               5. Alkaline phosphatase &gt; 1.25x ULN&#xD;
&#xD;
          -  History of or current malabsorption conditions (i.e., short bowel syndrome, active&#xD;
             Crohn's disease, celiac disease, etc.)&#xD;
&#xD;
          -  Neutropenia as defined by absolute neutrophil count &lt;1000 cells/mm3. Subjects with&#xD;
             neutrophil counts as low as 500 cells/mm3 are permitted if the reduction can be&#xD;
             documented to be due to the acute infectious process&#xD;
&#xD;
          -  Platelet count &lt;75,000/mm3. Subjects with platelet counts as low as 50,000/mm3 are&#xD;
             permitted if the reduction is historically stable&#xD;
&#xD;
          -  Coagulation tests &gt;1.5x ULN (PT, PTT, or INR). Subjects on anticoagulants with values&#xD;
             &gt; 1.5x ULN can be enrolled, provided these values are historically stable and within&#xD;
             the therapeutic range&#xD;
&#xD;
          -  History of alcohol or drug abuse in the past 2 years&#xD;
&#xD;
          -  History of seizure or currently receiving anti-seizure medication anytime in the past&#xD;
             year, or a seizure in the past year&#xD;
&#xD;
          -  History of ventricular arrhythmia&#xD;
&#xD;
          -  History of QTc prolongation (i.e., &gt;450msec) or observed QTc measurement at screening&#xD;
             &gt; 450msec, or a history of additional risk factors for Torsade de Pointe, such as&#xD;
             heart failure, hypokalemia, or familial history of Long QT syndrome&#xD;
&#xD;
          -  Require medications that may prolong the QTc interval&#xD;
&#xD;
          -  Require medications that affect absorption, including but not limited to sucralfate or&#xD;
             cimetidine&#xD;
&#xD;
          -  Require treatment with theophylline, probenecid, vitamin K antagonists (other than&#xD;
             warfarin; subjects must be on stable dose of warfarin and within therapeutic range)&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or breast feeding&#xD;
&#xD;
          -  Received any investigational drug or device within 30 days prior to study entry&#xD;
&#xD;
          -  Previously received zabofloxacin in a clinical trial&#xD;
&#xD;
          -  History of allergy or intolerability to fluoroquinolones&#xD;
&#xD;
          -  History of fluoroquinolone tendinopathy&#xD;
&#xD;
          -  Evidence of immediately life-threatening disease including, but not limited to current&#xD;
             or impending respiratory failure, acute heart failure, shock, acute coronary syndrome,&#xD;
             unstable arrhythmias, hypertensive emergency, acute hepatic failure, active&#xD;
             gastrointestinal bleeding, profound metabolic abnormalities (e.g., diabetic&#xD;
             ketoacidosis), or acute cerebrovascular events&#xD;
&#xD;
          -  Current condition or abnormality that, in the opinion of the investigator, would&#xD;
             compromise the safety of the subject or the quality of the data&#xD;
&#xD;
          -  Unable or unwilling to adhere to sthe study specified procedures and restrictions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toney</city>
        <state>Alabama</state>
        <zip>35773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>93616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keego Harbor</city>
        <state>Michigan</state>
        <zip>48320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belvidere</city>
        <state>New Jersey</state>
        <zip>078238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <zip>18974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>Community acquired pneumonia of moderate severity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

